Janux Therapeutics price to sales ratio JANX

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 42.4×
5-year median: 82.7×
Against its 5-year history: 5th; percentile: 0 is its lowest day, 100 its highest
5-year range: 32.9× to 196×
Peer median: 1.6×

Janux Therapeutics' price to sales ratio is 42.4× as of Oct 23, 2026.

That is below its 5-year median of 82.7×, lower than on 95% of days in the last 5 years.

Over that time it ranged from 32.9× in Nov 2023 to 196× in Nov 2024.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	42.4×	40.4×	96.2×
2025	85.7×	82.9×	188×
2024	182×	45.4×	196×
2023	58.5×	32.9×	124×
2022	74.3×	66.9×	173×

Against its peers

Companies in Drug Manufacturers - General nearest Janux Therapeutics' size, closest first, today.

Company	Price to sales ratio
JANXJanux Therapeutics	42.4×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
ABUSArbutus Biopharma	4.6×
COLLCollegium Pharmaceutical	0.9×
PCRXPacira BioSciences	1.9×
ANABAnaptysbio	n/m
PAHCPhibro Animal Health	1.0×
ANIPANI Pharmaceuticals	1.7×
CRMDCorMedix	1.3×
ZVRAZevra Therapeutics	4.3×
Peer median	1.6×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Janux Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.